In conclusion, the GRh2-functionalized liposomal platform developed in this study provided a promising strategy for effective BRD4-PROTAC delivery in breast cancer treatment, addressing critical challenges in current targeted therapies through its multifunctional design. The gene discussed is BRD4; the disease is breast cancer.